Coherus Biosciences (CHRS)
NASDAQ:CHRS
Want to see CHRS full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.39Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and clinical picture: robust year-over-year LOQTORZI revenue growth (61% YoY), record new patient starts, fully enrolled randomized HCC study, multiple tagmokitug cohorts actively accruing, and a $54M capital raise that strengthens liquidity. These achievements are tempered by near-term seasonality and weather-related revenue disruption, mixed external CCR8-class data that increase binary risk for tagmokitug, and the need for longer follow-up to demonstrate durability and survival for regulatory endpoints. Cost control and expense reductions improve runway, but modest cash depletion and the potential for multiple concurrent development needs remain monitoring items. Overall, the highlights (strong sales growth, pipeline progress, funded trials) outweigh the lowlights (Q1 weather impact, CCR8-class uncertainty, and data maturity concerns).Company Guidance
Strong Year-over-Year Sales Growth for LOQTORZI
LOQTORZI net sales increased 61% versus Q1 2025 with Q1 2026 net sales of $11.8M (down modestly QoQ from $12.4M in Q4 2025, a ~4.8% quarter-over-quarter decline attributed to seasonality and weather). Management forecasts ramp targets of ~$15M/quarter in 2026, $30–35M/quarter in 2027 and a peak market share of ~$44M/quarter (~$175M/year) by 2028.
Record New Patient Starts and Increased Account Penetration
Q1 saw all-time high new patient starts for LOQTORZI. Breadth and depth of ordering accounts increased 21% and treatment duration is increasing quarter-over-quarter, supporting management's multi-quarter demand growth outlook of 10%–15% average demand growth per quarter in 2026.
Pipeline Clinical Milestones: CATALYST-202 Fully Enrolled
Completed target accrual to the randomized CATALYST-202 (72-patient, 3-arm) first-line hepatocellular carcinoma study; initial data expected midyear. Prior casdozokitug triplet data showed ORR 38% and complete response 17% versus historical atezo/bev 30% ORR and 7.7% CR, supporting further development and biomarker analyses (including IL-27 and circulating tumor DNA).
Accelerating Tagmokitug Clinical Program
Multiple tagmokitug cohorts are actively accruing (40-patient HNSCC expansion, 40-patient upper GI adeno cohort, ESCC cohorts, MSS CRC cohort without liver mets); initial data for several cohorts anticipated midyear to H2 2026. The first nonproprietary combination with J&J pasritamig (prostate) is advancing, with first-patient expected in the fall.
Strong Pharmacology & Positioning for Tagmokitug
Company reports tagmokitug meets 'right drug' criteria: linear dose-dependent PK, target-binding potency, dose-dependent immune/pharmacodynamic effects, and an acceptable safety profile alone and combined with toripalimab — positioning it favorably amid mixed CCR8-class results from other developers.
Improved Cost Discipline and Strengthened Liquidity
Follow-on equity offering generated $54M of net proceeds (including full exercise of overallotment). Cash, cash equivalents and investments were $167M at quarter-end. Operating expense reductions: R&D from continuing operations of $21.5M (down from $24.4M, ~11.9% decrease YoY) and SG&A of $23.1M (down from $26.0M, ~11.2% decrease YoY), reflecting tighter spending discipline and exit from biosimilars.
CHRS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CHRS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | $1.95 | $1.71 | -12.31% |
Mar 09, 2026 | $1.93 | $1.95 | +1.04% |
Nov 06, 2025 | $1.49 | $1.34 | -10.07% |
Aug 07, 2025 | $0.88 | $0.82 | -7.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Coherus Biosciences (CHRS) report earnings?
Coherus Biosciences (CHRS) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Coherus Biosciences (CHRS) earnings time?
Coherus Biosciences (CHRS) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CHRS EPS forecast?
CHRS EPS forecast for the fiscal quarter 2026 (Q2) is -0.25.